Mandate

Vinge advises Actic Group AB (publ) in connection with its listing on Nasdaq Stockholm

Vinge has advised Actic Group AB (publ) (”Actic”) in connection with its listing on Nasdaq Stockholm. The prospectus was published on 28 March 2017 and the first day of trading on Nasdaq Stockholm was 7 April 2017.

The offer price was SEK 50.50 per share, corresponding to a market value for Actic of approximately SEK 800 million. The offer related to 8 613 860 shares, of which 5 346 534 were newly issued shares and 3 267 326 were existing shares which were offered by the selling shareholder Actic International S.à r.l., which is owned by IK 2007 Fund. The total value of the offer amounted to approximately SEK 500 million on the assumption that the oversubscription option is exercised in full.

Actic is a North European operator of health care facilities focusing on Sweden, Norway and Germany, and with a presence in Finland and Austria. As per 31 December 2016, Actic had approximately 211 000 members divided into 166 facilities in five countries with approximately 700 employees. During 2016, Actic’s total revenues amounted to approximately SEK 800 million. The company was formed in 1981 and its head office is situated in Solna.

Vinge’s team primarily consisted of Jonas Bergström, Jesper Schönbeck, David Andersson, Joel Wahlberg, Annika Nyberg Ekenberg and Christian Brelin. Linda Sengul, Johanna Wiberg and Marith Welin Berger provided advice regarding due diligence. Louise Brorsson Salomon, Helena Håkansson and Adam Sandberg provided advice relating to financing issues.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025